BioCentury
ARTICLE | Clinical News

Imfinzi-tremelimumab combo fails Phase III for head and neck cancer

December 7, 2018 4:24 PM UTC

In yet another setback for tremelimumab, AstraZeneca plc (LSE:AZN; NYSE:AZN) said the anti-CTLA-4 mAb in combination with PD-L1 inhibitor Imfinzi durvalumab missed the primary endpoint of improving overall survival (OS) compared with standard of care (SOC) chemotherapy in the Phase III EAGLE trial to treat squamous cell carcinoma of the head and neck (SCCHN).

Last month, AZ said tremelimumab plus Imfinzi missed the co-primary endpoint of improving OS in the Phase III MYSTIC trial as first-line treatment of non-small cell lung cancer (NSCLC) (see "Imfinzi Fails Again in MYSTIC Trial for First-Line NSCLC")...